| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Weng,Zhong-Jun | Chairman | 0.00% | TAIWAN HEALTH SPORT INVESTMENT CO., LTD. |
| Xie,Jin-Kun | Director | 1.21% | |
| Huang,Jun-Yi | Director | 0.05% | GREENSUMMIT CO., LTD. |
| Xie,Wen-Fang | Director | 0.00% | TAIWAN HEALTH SPORT INVESTMENT CO., LTD. |
| Zhang,Bo-Sheng | Director | 0.00% | TAIWAN HEALTH SPORT INVESTMENT CO., LTD. |
| Xie,Yi-Jing | Director | 16.84% | BAI JIA YUAN INVESTMENT CO., LTD. |
| Xu,Yin-Zhu | Independent Director | 0.00% | |
| Cai,Hui-Ming | Independent Director | 0.00% | |
| Gao,Jia-Liang | Independent Director | 0.00% |
Change Company Name to Jia Jie Biomedical Co., Ltd.
2024/03/18
Change Person in Charge to Chen,He-Shun
2023/07/19
Change Company Name to JIAJIE BIOTECHNOLOGY CO., LTD. (FORMER NAME: MURAD JIAJIE BIOTECHNOLOGY CO., LTD.)
2022/08/17
Change Person in Charge to Jin Zhi,Hong-Tou-Zi-You-Xian-Gong-Si
2020/06/11
Change Person in Charge to Li,Wen-Xiang
2020/03/24
Change Company Name to Jia Jie Biomedical Co., Ltd.
2019/07/29
Change Capital to 1,600,000,000
2019/07/29
Change Person in Charge to Lin,Jun-Zhang
2019/07/29
Change Person in Charge to Jiang,Rui-Long
2018/05/24
Change Person in Charge to
2018/05/16
Change Person in Charge to Zhong,Xiang-Feng
2016/07/20
Change Company Name to MU LA DE JIA JIE BIOTECH CO., LTD.
2013/11/29
Change Capital to 1,000,000,000
2011/10/27
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 132,864 | 537,070 | 332,758 |
| Operating cost | 85,021 | 363,722 | 215,123 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 47,843 | 173,348 | 117,635 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 47,843 | 173,348 | 117,635 |
| Operating expenses | 37,101 | 140,178 | 183,835 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 10,742 | 33,170 | -66,200 |
| Non-operating income and expenses | 10,979 | 192,315 | 212,749 |
| Net profit (loss) before tax | 21,721 | 225,485 | 146,549 |
| Income tax expense (benefits) | 7,462 | 9,335 | -475 |
| Net profit (loss) of ongoing business for the current period | 14,259 | 216,150 | 147,024 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 14,259 | 216,150 | 147,024 |
| Other comprehensive profit (loss), net | -557 | -8,549 | 3,816 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 13,702 | 207,601 | 150,840 |
| Net profit (loss) attributable to owners of parent company | 13,459 | 211,372 | 144,146 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | 800 | 4,778 | 2,878 |
| Comprehensive profit (loss) attributable to owners of parent company | 12,737 | 202,766 | 147,602 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | 965 | 4,835 | 3,238 |
| Basic earnings per share (yuan) | 0 | 2 | 1 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 12,934 | 44,346 | -4,488 |
| Net cash inflows (outflows) from investing activities | -185,269 | -128,145 | 2,548 |
| Net cash inflow (outflow) from financing activities | 359,317 | -158,769 | 234,569 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 397 | 1,086 | -3,739 |
| Increase (decrease) in cash and cash equivalents in the current period | 187,379 | -241,482 | 228,890 |
| Beginning balance of cash and cash equivalents | 112,942 | 354,424 | 125,534 |
| Ending balance of cash and cash equivalents | 300,321 | 112,942 | 354,424 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 718,005 | 348,336 | 437,305 |
| Non-current asset | 1,156,703 | 1,133,948 | 975,608 |
| Total asset | 1,874,708 | 1,482,284 | 1,412,913 |
| Current liability | 195,472 | 116,849 | 336,839 |
| Non-current liability | 5,700 | 6,233 | 5,853 |
| Total liability | 201,172 | 123,082 | 342,692 |
| share capital | 1,187,367 | 987,367 | 889,367 |
| Equity - secruity token | - | - | - |
| capital reserve | 251,051 | 91,051 | 58,303 |
| retained earning | 303,923 | 349,832 | 163,015 |
| Other equity | -97,956 | -97,234 | -63,815 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 1,644,385 | 1,331,016 | 1,046,870 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | 29,151 | 28,186 | 23,351 |
| Total Equity | 1,673,536 | 1,359,202 | 1,070,221 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 13 | 13 | 11 |
